Highlight
– Vutrisiran, an RNA interference agent, significantly improves clinical outcomes in transthyretin amyloidosis with cardiomyopathy (ATTR-CM).
– Treatment effects of vutrisiran on survival and cardiovascular events were consistent irrespective of prior tafamidis use.
– Patients on background tafamidis showed numerically smaller effect sizes but no significant interaction in outcomes.
– These findings support the rationale and need for prospective trials evaluating combination therapy with transthyretin stabilizers and RNA interference therapeutics.
